Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Peter O'Heeron
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15
- Beta
- 1.22
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -17.58
Financials
Net Income
$-4.12MEBITDA
$-4.03MFree Cash Flow
$-3.29MEPS (diluted)
$-1.09Shares Outstanding (diluted)
3.77M+167.3%Operating Expenses
$4.03MCash & Debt
$3.52MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-18.65M | $-8.35 |
| 2024 | $0.00 | $-11.16M | $-6.80 |
| 2023 | $0.00 | $-16.48M | $-11.80 |
| 2022 | $0.00 | $-5.12M | $-3.20 |
| 2021 | $0.00 | $-1.58M | $-0.97 |
| 2020 | $0.00 | $-1.17M | $-0.72 |
Valuation
FBLGhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (8)
- Newsprnewswire.com·7d ago·Neutral
…et Rich Plasma and Cytokines, with Claims Directed to Angiogenesis and Spinal Disc Regeneration HOUSTON, Sept. 29, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the European Patent Office has granted European Paten…
View source ↗ - Newsseekingalpha.com·13d ago·Positive
FibroBiologics, Inc. (FBLG) Discusses Strategy and Clinical Progress in Fibroblast-Based Cell Therapies for Chronic Diseases Transcript FibroBiologics, Inc. (FBLG) Discusses Strategy and Clinical Progress in Fibroblast-Based Cell Therapies for Chronic Diseases Transcript
View source ↗ - Newsprnewswire.com·35d ago·Neutral
…vers Methods of Promoting Disc Regeneration Using Components Derived from Stimulated Fibroblasts HOUSTON, Sept. 1, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO)…
View source ↗ - Newsproactiveinvestors.co.uk·39d ago·Negative
FibroBiologics advances diabetic ulcer trial with new drug shipment to Australia FibroBiologics (NASDAQ:FBLG), a clinical-stage biotechnology company, has released and shipped the third batch of its experimental drug product, CYWC628, to Australia to support an ongoing clinical trial for diabetic foot ulcers (DFUs). The compant describes the investigational treatment as a topically applied allogeneic cell therapy that uses donor fibroblasts, a type of specialized connective tissue cell, to accel…
View source ↗ - Newsprnewswire.com·40d ago·Negative
…cs Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial HOUSTON, Aug. 27, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the release of the third batch of its CYWC628 drug product…
View source ↗ - Newsprnewswire.com·43d ago·Positive
…y Sports Agent, Attorney, and Longtime Advocate for Human Longevity and Brain Health Joins Board HOUSTON, Aug. 24, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Leigh Steinberg to its Board of Directors. Widely regard…
View source ↗ - Newsprnewswire.com·49d ago·Neutral
…ls show cartilage repair within four weeks following a single injection of chondrocyte spheroids HOUSTON, Aug. 18, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced a breakthrough in its orthopedics laboratory using chondrocyte spheroids to…
View source ↗ - Newsprnewswire.com·56d ago·Neutral
FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets Patent has potential for applications beyond diabetes, including other cell and tissue transplantation procedures HOUSTON, Aug. 11, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for ch
View source ↗
Earnings
Fri, Oct 30(in 3 weeks)
Consensus estimate $-0.63 per share
Typical surprise -30.0% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Jul 31$-0.66 vs $-0.93beat
- Thu, Apr 30$-1.33 vs $-1.26miss
- Tue, Feb 24$-0.98 vs $-1.44beat
- Fri, Oct 31$-2.60 vs $-2.00miss
- Thu, Jul 31$-2.40 vs $-0.11miss
- Wed, May 14$-2.80 vs $-2.00miss
Estimates and results for FBLG via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by FBLG officers and directors.
- Bought
- $137k
- Sold
- —
8 trades
0 trades
- Khoja Hamidbought
- O'heeron Petebought
- O'heeron Petebought
- O'heeron Petebought
- Davis Jasonbought
- Garcia Ruben Abought
- Garcia Ruben Abought
- Khoja Hamidbought
27 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in FBLG.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.